-
New Research on PORT-77 for Erythropoietic Protoporphyria (EPP) Presented at ASH 2024
Phototoxicity and liver damage are significant challenges for individuals with Erythropoietic Protoporphyria (EPP), a rare genetic disorder caused by the accumulation of protoporphyrin IX (PPIX). At ASH 2024, Bhavik Shah…
-
ASCO GI 2025 | Professor Yanhong Deng’s Team Presents Two Colorectal Cancer Studies at ASCO GI 2025 – Expert Interpretation by Dr. Xiaoshuang Lü
To provide a deeper understanding of these important findings, Oncology Frontier meticulously compiled and analyzed the key insights from these studies. Additionally, Dr. Xiaoshuang Lü, a postdoctoral researcher from Professor…
-
Can Axillary Ultrasound Reliably Predict Nodal Status After Neoadjuvant Chemotherapy? Insights from the AXSANA Trial
At #SABCS24, Steffi Hartmann presented findings from the AXSANA registry trial (NCT04373655), the largest prospective study evaluating the diagnostic performance of axillary ultrasound (AUS) in initially node-positive breast cancer patients…
-
ASCO GI 2025 | Dr. Ying Yuan: BBCAPX Regimen as a Potential Immunotherapy Breakthrough for RAS-Mutant MSS mCRC with Liver Metastases
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) commenced in San Francisco on January 23, 2025. During the conference, Dr. Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine presented the latest survival data and subgroup analysis from the BBCAPX study. Oncology Frontier had the privilege of discussing the updated findings…
-
Investigating the Thrombotic Risks of a Highly Prevalent GRK5 Variant
A recent study presented at hashtag#ASH2024 explores the mechanistic insights and clinical implications of a widely prevalent GRK5 variant affecting platelet function. featuring Yanki Yarman, this research highlights how the…
-
Can a Ketogenic Diet Enhance CAR T-Cell Therapy?
New findings presented at ASH2024 suggest that a ketogenic diet and its key metabolite, β-hydroxybutyrate (BHB), may improve CAR T-cell antitumor function. In preclinical models, BHB fueled CAR T-cell metabolism,…
-
NRG-BR004 Trial: Atezolizumab in HER2+ Metastatic Breast Cancer
Presented at SABCS 2024 by Dr. Vicente Valero, the NRG-BR004 trial evaluated adding atezolizumab to first-line THP therapy in HER2+ metastatic breast cancer (MBC). Key Findings:PFS: 38.1 months (atezolizumab) vs.…
-
Dr. Hui Wei: Advances in Targeted Therapy for FLT3-Mutated AML | 2025 CSCO Hematologic Oncology Conference
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with FLT3 mutations among the most common molecular abnormalities, significantly impacting patient prognosis. As our understanding of AML pathogenesis deepens, novel targeted therapies, including FLT3 inhibitors, have emerged, offering new hope for patients with FLT3-mutated AML. From January 17 to 19, 2025, the “CSCO Leukemia,…
Connecting Medical Expertise through Media